{"id":64047,"date":"2026-04-27T20:48:17","date_gmt":"2026-04-27T12:48:17","guid":{"rendered":"https:\/\/flcube.com\/?p=64047"},"modified":"2026-04-27T20:48:18","modified_gmt":"2026-04-27T12:48:18","slug":"astrazeneca-secures-fda-approval-for-subcutaneous-saphnelo-in-systemic-lupus-erythematosus-after-addressing-supplemental-data-request","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64047","title":{"rendered":"AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request"},"content":{"rendered":"\n

AstraZeneca plc<\/strong> (NYSE: AZN<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved the subcutaneous (SC) formulation of Saphnelo\u2122 (anifrolumab)<\/strong> for the treatment of adult patients with systemic lupus erythematosus (SLE)<\/strong> in combination with standard therapy.<\/p>\n\n\n\n

The approval follows a two-month regulatory review extension during which the FDA requested additional supplemental information<\/strong>, now resolved to the agency\u2019s satisfaction. The decision is based on the Phase III TULIP-SC trial<\/strong>, which demonstrated that SC Saphnelo achieved statistically significant and clinically meaningful reductions in SLE disease activity<\/strong> versus placebo in patients with mild-to-moderate to severe disease already receiving background therapy.<\/p>\n\n\n\n

Regulatory & Clinical Profile<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Drug<\/strong><\/td>Saphnelo\u2122 (anifrolumab) \u2013 first-in-class, fully human monoclonal antibody<\/td><\/tr>
Mechanism<\/strong><\/td>Binds type I interferon (IFN) receptor subunit \u2192 blocks all type I IFN signaling<\/td><\/tr>
Formulation<\/strong><\/td>Subcutaneous injection (self-administered)<\/td><\/tr>
Indication<\/strong><\/td>Adult SLE (on top of standard therapy)<\/td><\/tr>
Pivotal Trial<\/strong><\/td>TULIP-SC Phase III \u2013 met primary and key secondary endpoints<\/td><\/tr>
Safety<\/strong><\/td>Consistent with intravenous (IV) Saphnelo; no new safety signals<\/td><\/tr>
Regulatory Path<\/strong><\/td>Approved after addressing FDA\u2019s February 2026 data request<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context: Unmet Need in SLE<\/h2>\n\n\n\n